Shares of Aeterna Zentaris (AEZS) crater - down 63.1% premarket - after Keryx announces a failure of its perifosince drug to meet endpoints in a Phase 3 clinical trial conducted at 65 U.S. sites. Aetenera Zentaris has a license agreement with Keryx over the drug.
Shares of Aeterna Zentaris (AEZS) crater - down 63.1% premarket - after Keryx announces a...
From other sites
at CNBC.com (Nov 6, 2014)
at CNBC.com (Jan 9, 2013)
at CNBC.com (Mar 6, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs